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Abstract
During episodes of hypoxia and inflammation, polymorphonuclear leukocytes (PMN) move into underlying tissues by
initially passing between endothelial cells that line the inner surface of blood vessels (transendothelial migration, TEM).
TEM creates the potential for disturbances in vascular barrier and concomitant loss of extravascular fluid and resultant
edema. Recent studies have demonstrated a crucial role for nucleotide metabolism and nucleoside signaling during
inflammation. These studies have implicated multiple adenine nucleotides as endogenous tissue protective mechanisms
in vivo. Here, we review the functional components of vascular barrier, identify strategies for increasing nucleotide
generation and nucleoside signaling, and discuss potential therapeutic targets to regulate the vascular barrier during
inflammation.
Abbreviations: AMP – 50-adenosine monophosphate; APCP–50-alpha, beta-methylenediphosphate; ATP–5-adenosine
triphosphate; BMK1–big mitogen-activated protein kinase-1; cAMP–cyclic adenosine monophosphate; CD39–ecto-
apyrase; CD73–ecto-50-nucleotidase; ERK5–extracellular signal-regulated kinase 5; HBP–heparin binding protein; HIF–
hypoxia inducible factor; ICAM–intercellular adhesion molecule; MAPK–mitogen activated protein kinase; mGluR–
metabotropic glutamate receptor; PMN–polymorphonuclear leukocyte (neutrophil); TEM–transendothelial migration;
VASP–vasodilator-stimulated phosphoprotein
Introduction
Approximately 70 million PMN exit the vasculature per
minute [1]. These inflammatory cells move into underlying
tissue by initially passing between endothelial cells that
line the inner surface of blood vessels. This process,
referred to as transendothelial migration (TEM), is particu-
larly prevalent in inflamed tissues, but also occurs as a
natural process of leukocyte mobilization (e.g., bone
marrow extravasation). Understanding the biochemical de-
tails of leukocyteYendothelial interactions is currently an
area of concentrated investigation, and recent studies using
genetically modified animals have identified specific mol-
ecules which function as Fbottlenecks_ in the control of the
inflammatory response [2]. For example, detailed studies
have revealed that the process of leukocyte TEM entails a
concerted series of events involving intimate interactions
of a series of leukocyte and endothelial glycoproteins that
include selectins, integrins, and members of the immuno-
globulin supergene family [3Y5]. Histologic studies of
TEM reveal that PMN initially adhere to endothelium,
move to nearby inter-endothelial junctions via diapedesis,
and insert pseudopodia into the inter-endothelial para-
cellular space [6].
SuccessfulTEMisaccomplishedbytemporaryPMNself-
deformation with localizedwidening of the inter-endothelial
junction. Particularly during episodes of inflammation,
TEM has the potential to disturb vascular barrier function
and give rise to extravascular fluid extravasation and edema.
However,several innate mechanismshave been describedto
dampen fluid loss during PMNYendothelial interactions [7].
For example, following TEM, adjacent endothelial cells
appear to Freseal,_ leaving no residual inter-endothelial
gaps [6]. These histologic studies are consistent with the
observation that leukocyte TEM may result in little or no
change in endothelial permeability to macromolecules
[8Y12]. In the absence of this tight and dynamic control of
endothelial morphology and permeability, inter-endothelial
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increases in endothelial permeability (Figure 1). However,
only limited information exists regarding the biochemical
events which maintain and dynamically regulate endothelial
permeability in the setting of either PMN activation or TEM
[5, 6]. Current studies reveal that activated PMN release
soluble factor(s) which support maintenance of endothelial
permeability during PMNYendothelial interactions [7, 13,
14]. Several crosstalk pathways have been identified to
protect endothelial permeability during inflammation and
hypoxia and to dampen excessive fluid loss into the inter-
stitium. Such innate protective pathways share the common
strategy to increase intravascular adenosine concentrations
and adenosine signaling within the inflamed or hypoxic
vasculature [7, 14Y18].
Structural and functional elements
of the vascular barrier
The predominant barrier (õ90%) to movement of macro-
molecules across a blood vessel wall is presented by the
endothelium [19, 20]. Passage of macromolecules across a
cellular monolayer can occur via either a paracellular route
(i.e., between cells) or a transcellular route (i.e., through
cells). In non-pathologic endothelium, macromolecules
such as albumin (molecular weight õ65 kD) appear to cross
the cell monolayer by passing between adjacent endothelial
cells (i.e., paracellular) although some degree of trans-
cellular passage may also occur [21, 22]. Endothelial per-
meability is determined by cytoskeletal mechanisms that
regulate lateral membrane intercellular junctions [23, 24].
Tight junctions, also known as zona occludens, com-
prise one type of intercellular junction. Transmembrane pro-
teins found within this region which function to regulate
paracellular passage of macromolecules include the proteins
occludin, and members of the junctional adhesion molecule
(JAM) and claudin families of proteins [18]. Tight junctions
form narrow, cell-to-cell contacts with adjacent cells and
comprise the predominant barrier to transit of macro-
molecules between adjacent endothelial cells [25]. Endo-
thelial macromolecular permeability is inversely related to
macromolecule size. Permeability is also dependent on the
tissue of origin. For example, endothelial cells in the
cerebral circulation (i.e., bloodYbrain barrier) demonstrate
an exceptionally low permeability [26, 27]. Endothelial
permeability may increase markedly upon exposure to a
variety of inflammatory compounds (e.g., histamine,
thrombin, reactive oxygen species, leukotrienes, bacterial
endotoxins) or adverse conditions (e.g., hypoxia, ischemia)
[6, 19]. Reversible increases in endothelial permeability are
produced by administration of cytochalasin or other agents
that disrupt cytoskeletal microfilaments [19, 28]. Likewise,
increases in endothelial permeability are accompanied by
disruption of peripheral actin microfilaments and formation
of gaps between adjacent endothelial cells [19, 28].
Administration of compounds that decrease endothelial
permeability result in an irregular endothelial cell contour,
greater convolution of cell margins, closer cell-to-cell con-
tact, and increased surface area and cell perimeter [28].
These changes in cell morphology are accompanied by a
loss of F-actin in stress fibers, Fruffling_ of dense peripheral
bands of F-actin, and increase in the polymerized actin pool
without significant changes in total F-actin endothelial cell
content [23, 24]. Interestingly, these changes in intracel-
lular actin are similar to those observed during PMN
transendothelial migration [29]. By comparison, thrombin-
induced increases in permeability result in a centralization
(and peripheral loss) of F-actin. Both of these changes
(permeability and F-actin distribution) are inhibited by
isoproterenol [30]. Phallacidin, an F-actin-stabilizing com-
pound, also markedly attenuates thrombin-induced in-
creases in permeability and accompanying morphologic
changes (Figure 1).
In addition to the above components of the vascular
barrier, the glycocalyx may play a role in determining
movements of fluid and macromolecules across the endo-
thelium. The endothelial glycocalyx is a dynamic extracel-
lular matrix composed of cell surface proteoglycans,
glycoproteins, and adsorbed serum proteins, implicated in
the regulation and modulation of capillary tube hematocrit,
permeability, and hemostasis [31]. As such, increased
paracellular permeability of such molecules as water,
albumin and hydroxyethyl starch can be observed following
experimental degradation of the functional components of
the glycocalyx [32], and functional components of this
glycocalyx may be dynamically regulated by endogenous
mediators such as adenosine [33].
Vascular barrier during inflammation
Ongoing inflammatory responses are characterized by dra-
matic shifts in tissue metabolism. These changes include
large fluctuations in energy supply and demand and di-
minished availability of oxygen [34]. Such shifts in tissue
metabolism result, at least in part, from profound recruit-
ment of inflammatory cell types, particularly myeloid cells
such as neutrophils (PMN) and monocytes. The majority of
inflammatory cells are recruited to, as opposed to being
resident at, inflammatory lesions, and myeloid cell migra-
tion to sites of inflammation are highly dependent on
hypoxia-adaptive pathways [34, 35]. Consequently, much
recent attention has focused on understanding how meta-
bolic changes (e.g., hypoxia) relate to the establishment
and propagation of the inflammatory response (Figure 2).
As outlined above, many parallels exist between hypoxic
and inflamed tissues [36]. For example, during episodes of
hypoxia, polymorphonuclear leukocytes (PMN) are mobi-
lized from the intravascular space to the interstitium, and
such responses may contribute significantly to tissue
damage during consequent reperfusion injury [13, 37, 38].
Moreover, emigration of PMN through the endo- and
epithelial barrier may lead to a disruption of such tissue
barriers [39Y41] and such a setting creates the potential for
extravascular fluid leakage and subsequent edema forma-
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by hypoxia-inducible factor (HIF) may serve as a barrier-
protective element during inflammatory hypoxia. For exam-
ple, experimental studies of murine inflammatory bowel
diseases have revealed extensive mucosal hypoxia and
concomitant HIF-1 activation during colitis [44]. Mice
engineered to express decreased intestinal epithelial HIF-
1 exhibit more severe clinical symptoms of colitis, while
increased HIF levels were protective in these parameters.
Furthermore, colons with constitutive activation of HIF dis-
played increased expression levels of HIF-regulated barrier-
protective genes (multidrug resistance gene-1, intestinal
trefoil factor, CD73), resulting in attenuated loss of barrier
during colitis in vivo. Such studies identify HIF as a critical
factor for barrier protection during mucosal inflammation
and hypoxia [44].
Barrier disruptive pathways
Macromolecule transit across blood vessels has evolved to
be tightly controlled. Relatively low macromolecular per-
meability of blood vessels is essential for maintenance of a
physiologically optimal equilibrium between intravascular
and extravascular compartments [45, 46]. Endothelial cells
are primary targets for leukocytes during episodes of
infection, ischemic or traumatic injury, which all together
can result in an altered barrier function. Disturbance of
endothelial barrier during these disease states can lead to
deleterious loss of fluids and plasma protein into the extra-
vascular compartment. Such disturbances in endothelial
barrier function are prominent in disorders such as shock
and ischemiaYreperfusion and contribute significantly to or-
gan dysfunction [47Y51].
Figure 2. Proposed model of coordinated nucleotide metabolism and nucleoside signaling in posthypoxic endothelial cells. In areas of ongoing
inflammation, diminished oxygen supply coordinates the induction of CD39, CD73, and AdoRA2B. At such sites, activated PMN provide a readily
available extracellular source of ATP, that through two enzymatic steps results in the liberation of extracellular adenosine. Activation of surface AdoR
functions to promote the re-establishment of vascular integrity. Under such circumstances, PMN appear to Bclose the door after exiting.^
Figure 1. Neutrophil (PMN) transendothelial migration (TEM). PMN exit the circulation and move into underlying tissue by passing between
endothelial cells. During this process, inter-endothelial gaps have the potential to increase vascular permeability, with resultant tissue edema and organ
dysfunction. While the endogenous mechanism(s) which regulate these pathways remain poorly understood, work in recent years has revealed new and
previously unappreciated targets for potential therapeutic intervention.
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a number of soluble mediators, which dynamically influ-
ence vascular permeability during transmigration. As such,
PMN have been shown to liberate factors that can either
disrupt or protect the endothelial barrier: For example, it
was recently shown that activation of PMN through b2-
integrins elicits the release of soluble factor(s) which
induce endothelial cytoskeletal rearrangement, gap forma-
tion and increased permeability [52]. This PMN-derived
permeabilizing factor was subsequently identified as
heparin-binding protein (HBP), also called azurocidin or
CAP37 [52], a member of the serprocidin family of
cationic peptides [53]. HBP, but not other neutrophil
granule proteins (e.g., elastase, cathepsin G), was shown
to induce Ca
2+-dependent cytoskeletal changes in cultured
endothelia and to trigger macromolecular leakage in vivo.
Interestingly, HBP regulation of barrier may not be
selective for PMN, and in fact, endothelial cells themselves
are now a reported source of HPB [54]. It is therefore
possible that endothelia may self-regulate permeability
through HBP under some conditions, and that mediators
found within the inflammatory milieu may also increase
endothelial permeability.
Similarly, PMNs were observed to significantly alter
endothelial permeability by release of glutamate, following
FMLP activation. This crosstalk pathway appears to be of
particular importance for the regulation of the vascular
barrier of the brain (BbloodYbrain barrier^). In fact,
treatment of human brain endothelia with glutamate or
selective, mGluR group I or III agonists resulted in a time-
dependent loss of phosphorylated vasodilator-stimulated
phosphoprotein (VASP) and significantly increased endo-
thelial permeability. Glutamate-induced decreases in brain
endothelial barrier function and phosphorylated VASP
were significantly attenuated by pretreatment of human
brain endothelia with selective mGluR antagonists. Even in
an in vivo hypoxic mouse model, the pretreatment with
mGluR antagonists significantly decreased fluorescein
isothiocyanateYdextran flux across the bloodYbrain barrier,
suggesting that activated human PMNs release glutamate
and that endothelial expression of group I or III mGluRs
function to decrease human brain endothelial VASP phos-
phorylation and barrier function [13].
A recently described gene regulatory pathway revealed a
critical role for BMK1/ERK5 in maintaining the endothe-
lial barrier and blood vessel integrity: A targeted deletion
of big mitogen-activated protein kinase1 gene (BMK1)
(also known as ERK5, member of the MAPK family), in
adult mice leads to disruption of the vascular barrier.
Histological analysis of these mice revealed that, after
BMK1 ablation, hemorrhages occurred in multiple organs
in which endothelial cells lining the blood vessels became
round, irregularly aligned, and, eventually, apoptotic. In
vitro removal of BMK1 protein also led to the death of
endothelial cells partially due to the deregulation of
transcriptional factor MEF2C, which is a direct substrate
of BMK1. Additionally, endothelial-specific BMK1-dele-
tion leads to cardiovascular defects identical to that of
global BMK1-deletion. Taken together, these studies
identify the BMK1 pathway as critical for endothelial
function and for maintaining blood vessel integrity [55].
Barrier protective pathways
Acute increases in vascular permeability to macromo-
lecules closely coincides with tissue injury of many
etiologies, and can result in fluid loss, edema, and organ
dysfunction [19, 56, 57]. Previous studies have indicated
that extracellular nucleotide metabolites may function as
an endogenous protective mechanism during hypoxia and
ischemia [58Y60]. One important factor may be increased
production of endogenous adenosine, a naturally occurring
anti-inflammatory agent [60Y62]. Several lines of evidence
support this assertion. First, adenosine receptors are widely
expressed on target cell types as diverse as leukocytes,
vascular endothelia, and mucosal epithelia and have been
studied for their capacity to modulate inflammation [63].
Second, murine models of inflammation provide evidence
for adenosine receptor signaling as a mechanism for
regulating inflammatory responses in vivo. For example,
mice deficient in the A2A-adenosine receptor (AdoRA2A)
show increased inflammation-associated tissue damage
[64]. Third, hypoxia is a common feature of inflamed
tissues [34] and is accompanied by significantly increased
levels of adenosine [65Y67]. At present, the exact source of
adenosine is not well defined, but likely results from a
combination of increased intracellular metabolism and
amplified extracellular phosphohydrolysis of adenine
nucleotides via surface ecto-nucleotidases.
The vascular endothelium is the primary interface
between a hypoxic insult and the surrounding tissues. At
the same time, the endothelium is central to the orchestra-
tion of leukocyte trafficking in response to chemotactic
stimuli. This critical anatomic location places vascular
endothelial cells in an ideal position to coordinate extracel-
lular metabolic events important to endogenous anti-
inflammatory responses. We recently identified a neutro-
philYendothelial cell crosstalk pathway that is coordinated
by hypoxia. This pathway utilizes extracellular nucleotide
substrates, liberated from different cell types. Extracellular
ATP release has been shown from endothelial cells,
particularly under sheer conditions or hypoxia. In addition,
fMLP activated neutrophils can release ATP, however the
exact mechanism through that these cells release ATP
remains currently unknown (see below) [14, 47]. Activated
platelets comprise an additional source for extracellular
adenine nucleotides [68, 69]. The role of endothelial CD39
(Ecto-apyrase, conversion of ATP/ADP to AMP) has been
viewed as a protective, thromboregulatory mechanism for
limiting the size of the hemostatic plug [69, 70]. Metabo-
lism of adenine nucleotides derived from activated plate-
lets is crucial in limiting excessive platelet aggregation and
thrombus formation [71, 72]. Similarly, excessive platelet
accumulation and recruitment can be treated with the use
of soluble forms of CD39 [73, 74]. Moreover, a thrombo-
regulatory role was demonstrated in a model of stroke,
where cd39-null mice showed increased infarction size that
was reduced by treatment with soluble CD39 [75].
232 T. Weissmuller et al.Surprisingly, targeted disruption of cd39 resulted in
prolonged bleeding and increased vascular leak and fibrin
deposition in hypoxemia [76], suggesting a dual role for
ATP metabolism by CD39 in modulating hemostasis and
thrombotic reactions. Moreover, this observation may be
related to an activation and desensitization of the purinergic
typeP2Y1 receptor. Activation of the P2Y1-platelet receptor
appears to be crucial in the activation process of platelets.
As such, P2Y1 deficient mice exhibit signs of prolonged
bleeding time and resistance to thromboembolism [77]. In
contrast to these studies, we observed a barrier-protective
influence during hypoxia that was not related to the activa-
tion of PX receptors, but to a downstream metabolism and
signaling of ATP metabolites (esp. adenosine).
Extracellular ATP is readily converted on the endothelial
surface to adenosine, due to the enzymatic function of
CD39 and CD73 (50-ecto-nucleotidase, conversion of AMP
to adenosine). Such adenosine binds to surface expressed
PMN adenosine receptors to limit excessive accumulation
of PMN within tissues, and as such, functions as a feed-
back loop to attenuate potential tissue injury [14]. With
regard to this latter point, it was recently shown that hy-
poxia coordinates both, transcriptional and metabolic
control of the surface ecto-nucleotidases CD39 and CD73
[14, 15, 78], and as such, significantly amplifies the extra-
cellular production of adenosine from adenine nucleotide
precursors. In fact when using cd39- and cd73-null animals
we found that extracellular adenosine, produced through
adenine nucleotide metabolism during hypoxia, is a potent
anti-inflammatory signal for PMN in vitro and in vivo.
These findings identify CD39 and CD73 as critical control
points for endogenous adenosine generation and implicate
this pathway as an innate mechanism to attenuate excessive
tissue PMN accumulation [14].
In addition to a role in limiting excessive neutrophil tissue
accumulation,CD39andCD73arealsocriticalcontrolpoints
for vascular permeability. For the purpose of investigating
overallorganvascularpermeability,weusedEvan’sbluedye,
whichtightlybindstoplasmaalbumin[79]. To do this, mice
were administered 0.2% Evan’s blue dye (0.5% in PBS)
by intravenous tail vein injection, subjected to room air
(normoxia) or normobaric hypoxia (8% O2/92% N2). At
the end of exposure, animals were anesthetized, heparin-
ized (50 U by i.p. injection) and fluid overloaded (3 cc
normal Ringer’s solution i.p.). Animals were then exsan-
guinated by femoral cut-down to flush all vascular beds,
and tissues were harvested. Tissues were rinsed in PBS,
and Evan’s blue was extracted with formamide at 56 -C for
2 h, and quantified at 610 nm with subtraction of reference
absorbance at 450 nm. This model entails the quantifica-
tion of formamide-extractable Evans blue [80] from tissues
of mice as a readout for overall vascular permeability of
different organs. In fact we found that vascular permeabil-
ity in tissues derived from animals subjected to normobaric
hypoxia (8% O2/92% N2) ranged from two to four-fold
more permeant to Evans blue than normoxic controls [14].
In order to identify the role of CD73 in vascular
permeability, we used this model in wild-type or cd73
j/j
mice administered either vehicle or the CD73 inhibitor
a,b-methylene ADP (APCP). These studies revealed a
profound increase of hypoxia-elicited dysfunction of the
vascular barrier in different organs (lung, heart, intestine,
kidneys) following CD73 inhibition or deletion. Vascular
leak associated with hypoxia was, at least in part, reversed
by reconstitution with soluble 50-nucleotidase and adeno-
sine receptor agonists in the cd73-null mice. Histological
examination of lungs from hypoxic cd73
j/j revealed
perivascular interstitial edema associated with inflamma-
tory infiltrates surrounding larger pulmonary vessels [81].
Taken together, these studies identify CD73 as a critical
mediator of vascular permeability in vivo. When measuring
vascular permeability during hypoxia in mice with targeted
deletion of CD39, similar increases in vascular barrier
function could be observed in different organs [14]. Taken
together, these studies have identified adenosine generation
of the hypoxic vasculature via nucleotide-phosphohydroly-
sis as a critical cellular strategy to generate adenosine and
maintain vascular barrier function.
Influence of adenosine receptor activation on endothelial
barrier function
In vitro studies of endothelial permeability suggested, that
activation of a specific endothelial adenosine receptor, the
AdoRA2B, leads to a barrier resealing response following
PMN transmigration [7]. Thus we were able to show that of
the four different adenosine receptors that are expressed by
endothelia, only the AdoRA2B is selectively induced by
hypoxia [14]. Activation of the AdoRA2B is associated
with increases in intracellular cAMP concentration due to
the activation of the adenylate cyclase [60]. By inhibition
of cAMP formation, the resealing of the endothelial barrier
during PMN transmigration can be obviated [7]. Such
increases in cAMP following activation of the AdoRA2B
lead to an activation of protein kinase A (PKA) [18].
Further studies revealed a central role of PKA-induced
phosphorylation of vasodilator-stimulated phosphoprotein
(VASP), a protein responsible for controlling the geometry
of actin-filaments [82]. Adenosine-receptor mediated phos-
phorylation of VASP is responsible for changes in the
geometry and distribution of junctional proteins, thereby
affecting the characteristics of the junctional complex and
promoting increases in barrier function [18, 83].
Inflammatory hypoxia
Hypoxia and vascular barrier function
A number of studies have identified perturbations of
endothelial permeability associated with hypoxia [84, 85].
In addition, tissue hypoxia has been implicated as a
contributing factor to inflammatory diseases initiated at
the vascular surface. For example, ongoing inflammatory
responses are characterized by dramatic shifts in tissue
metabolism, including lactate accumulation, increased
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oxygen [86Y88]. However, the exact mechanism by which
hypoxia causes changes in vascular permeability remains
the center of debate. In addition to the observation that
hypoxia causes a disruption of the vascular barrier, several
studies were able to identify hypoxia-elicited crosstalk
pathways, that are involved in maintaining the vascular
barrier and limiting excessive inflammatory responses. As
outlined above, targeted disruption of such pathways is
associated with dramatic increases in vascular permeability
during hypoxia exposure and increases in myeloid cell
accumulation within the hypoxic tissues [14, 15, 47, 81].
Increases in inflammatory cell accumulation
during hypoxia
During episodes of hypoxia or during ischemia-reperfu-
sion, the PMN influx across the protective endothelium
creates the potential of endothelial barrier dysfunction, loss
of fluid and edema formation [40, 89]. The myeloid cell
migration to sites of inflammation are highly dependent on
hypoxia adaptive pathways [34] and HIF-1a plays a critical
role in this process. This transcription factor consists of two
subunits HIF-1a and HIF-1b. Under conditions such as
normoxia, the HIF-1a subunit undergoes mechanisms of
enzymatic degradation. In contrast to its degradation during
non-hypoxic states, degradation of the a subunit is inhibited
under hypoxic conditions, leading to rapid accumulation of
the protein. HIF-1a and HIF-1b dimerize to the active
protein that translocates to the nucleus and binds to an
hypoxia response element within the promoter region of
target genes, thereby altering the transcription and transla-
tion of specific hypoxia elicited gene products [90].
Moreover, previous studies demonstrate, that HIF-1a is
essential for myeloid cell-mediated inflammation. As out-
lined above, metabolic shifts during inflammation can
result in significant tissue hypoxia, with resultant induction
of hypoxia-responsive genes. As such, recent studies show
that leukocyte functional responses are influenced by
hypoxia on a transcriptional level. Increases of leukocyte
accumulation within hypoxic tissues are transcription-
dependent and can be specifically blocked by antibodies
directed against b2-integrins. In addition, analysis of the
b2-integrin mRNA and protein shows a dramatic increase
with hypoxia. Subsequent studies identified a binding site
for hypoxia-inducible factor 1 (HIF-1) in the CD18 gene.
This gene encodes the subunit common to all four known
types of b2-integrin heterodimer. HIF-1 binding was
demonstrated in vivo, and mutational analysis of the HIF-
1 site within the CD18 promoter resulted in a loss of
hypoxia inducibility, suggesting that hypoxia induces
leukocyte b2-integrin expression and function by transcrip-
tional mechanisms dependent upon HIF-1 [35]. Moreover,
myeloid cellular ATP-pools are significantly reduced in the
absence of HIF-1a, leading to profound impairment of
myeloid cell aggregation, motility, invasiveness and bac-
terial killing [34]. Shifts in tissue metabolism result, at
least in part, from extensive recruitment of inflammatory
cells, particularly myeloid cells such as neutrophils (PMN)
and monocytes [36]. However, the direct relationship
between PMN activation and increased endothelial perme-
ability is not clear. While PMN accumulation and in-
creased vascular permeability are often coincidental,
particularly at sites of inflammation/hypoxia, PMN activa-
tion can occur with limited or no net changes in endothelial
permeability [8Y10, 12]. Moreover, while PMN depletion
has been demonstrated to decrease organ injury in some
models of ischemia and reperfusion [91], PMN have been
demonstrated to exert a protective effect in other models.
Therefore, further information regarding PMN-endothelial
cell interactions and their influence on endothelial perme-
ability may provide a better understanding of the regulation
of endothelial permeability.
Purine signaling during inflammation and hypoxia
PMN release nucleotides
As stated earlier, the transendothelial migration of PMN
during episodes of inflammation and hypoxia can be as-
sociated with fluid accumulation, edema and organ dys-
function as a cause of increased vascular permeability.
During TEM, neutrophils primarily interact with endothe-
lial cells and it is well documented that transmigration of
neutrophils may lead to an alteration of barrier function.
However their interactions with the endothelium do not
inevitably result in endothelial barrier dysfunction: there is
also evidence that PMN do not affect vascular permeability
despite extensive non-inflammatory PMNYendothelial ad-
hesion and subsequent transendothelial PMN migration.
Although many studies indicate that activated PMN lead
rather to disruption of the endothelial barrier, an increase
of endothelial barrier permeability upon exposure to
activated PMN has also been demonstrated [7, 14]. These
studies show that PMN derived soluble mediators like
adenosine and AMP are capable to increase the endothelial
barrier function via activation of the AdoRA2B adenosine-
receptor [59]. In addition, we showed that neutrophils also
release ATP following activation, and such ATP is coor-
dinately hydrolyzed to adenosine at the endothelial cell
surface particularly under hypoxic conditions by hypoxia-
induced CD39 and CD73 [14]. Several mechanisms for
ATP release have been proposed, including direct transport
through ATP-binding cassette (ABC) proteins, transport
through connexin hemichannels, as well as vesicular
release [92]. At present, the mechanism by which leuko-
cytes release ATP remains unclear and is the subject of
ongoing studies. Moreover, studies directed at understand-
ing extracellular metabolism of nucleotides in cell and
tissue responses now suggest that a number of different
cells can release ATP in an active manner [93]. In addition
to PMN, also activated platelets comprise an important
source for extracellular adenine nucleotides [68, 69]. How-
ever, their relative contribution to regulating the vascular
barrier or inflammation is currently not clear.
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The major pathway for extracellular hydrolysis of ATP and
ADP is the ecto-nucleoside triphosphate diphosphohydro-
lase (NTPDase) [94], previously identified as ecto-ATPase,
ecto-ATPDase or CD39 [95, 96]. In addition to modulating
extracellular nucleoside generation, CD39 has been con-
sidered in the modulation of platelet purinoreceptor
activity by the sequential hydrolysis of extracellular ATP
or ADP to AMP [96, 97]. This thromboregulatory potential
of CD39 has been demonstrated by the generation of
mutant mice with disruption of the CD39 gene [76], and
by a series of experiments where high levels ATPDase ex-
pression are attained by adenoviral vectors in the injured
vasculature [98Y100].
Ecto-50-nucleotidase (CD73) is a membrane bound gly-
coprotein which functions to convert the adenine nucleotide
AMP into adenosine, which in turn can activate transmem-
brane adenosine receptors or can be internalized through
dipyridamole-sensitive carriers [60]. These pathways have
been shown to result in such diverse endpoints as regu-
lation of endothelial barrier [7], stimulation of epithelial
electrogenic chloride secretion (responsible for mucosal
hydration) [101], and promotion of lymphocyteY endothe-
lial adhesion [102]. Targeted over expression of lympho-
cyte CD73 has recently revealed that increased adenosine
resulting from enhanced CD73 expression could contribute
to thymocyte apoptosis in adenosine deaminase deficiency
[103]. Endothelial cells of many origins express constitu-
tive CD73. The primary function attributed to endothelial
CD73 has been catabolism of extracellular nucleotides, al-
though CD73 may also mediate lymphocyte binding under
some circumstances [102].
As outlined above, multiple cell types release adenine
nucleotides under conditions of limited oxygen availability.
Extracellular nucleotides are metabolized to adenosine by
CD39 and CD73 and subsequent activation of surface ade-
nosine receptors has been shown to regulate endothelial and
epithelial barrier function [7]. Microarray RNA analysis
revealed an increase in CD73 and CD39 in hypoxic endo-
thelial and epithelial cells [14, 15]. Metabolic studies of
CD39/CD73 function revealed that hypoxia enhances
CD39/CD73 function as much as six-fold over normoxia.
Examination of the CD73 gene promoter identified a bind-
ing site for hypoxia-inducible factor-1 (HIF-1) and inhibi-
tion of HIF-1alpha expression by antisense oligonucleotides
resulted in significant inhibition of hypoxia-inducible
CD73 expression. Studies using luciferase reporter con-
structs showed a significant increase in activity in cells sub-
jected to hypoxia, which was lost in truncated constructs
lacking the HIF-1 site. Mutagenesis of the HIF-1alpha
binding site resulted in a nearly complete loss of hypoxia-
inducibility. In vivo studies in a murine hypoxia model
revealed that hypoxia-induced CD73 may serve to protect
the epithelial [15] and endothelial [81] barrier, since the
CD73 inhibitor alpha,beta-methylene ADP (APCP) pro-
motes increased intestinal permeability and cd73
j/j mice
show increased vascular permeability during hypoxia
exposure. These results identify a HIF-1-dependent regu-
latory pathway for CD73 and indicate the likelihood that
CD39/CD73 protects the epithelial and vascular barrier
during hypoxia [14, 15, 81].
Adenosine concentrations in hypoxia
Extracellular adenosine has been widely implicated in
adaptive responses to hypoxia. Thus, it is well documented
that adenosine tissue and plasma levels are increased
during hypoxia, however, mechanisms of this response
have yet to be further elucidated [66, 104]. For example, in
human volunteers exposed to ambient hypoxia (SpO2 =
80% over 20 min), plasma adenosine concentrations
increased from 21 to 51 nM in the presence of dipyrida-
mole, an inhibitor of adenosine reuptake [105]. Similarly,
when measuring adenine nucleotide concentrations in
neurally and vascularly isolated, perfused skeletal muscles
of anesthetized dogs, normobaric hypoxia is associated
with increases of adenosine in the venous blood, but not of
AMP, ADP or ATP [106]. A possible role for adenosine
during hypoxia may include vasodilatory characteristics.
For instance, it has been suggested that elevations in
intracellular nitric oxide as a result of AdoRA1 activation
may be responsible for the vasodilatory properties of ade-
nosine [107Y109]. Due to its vasodilator properties, in-
creases in adenosine tissue concentrations during hypoxia
may promote blood flow to hypoxic tissues, thereby pro-
viding an innate adaptive pathway to hypoxia. In addition,
there is evidence that hypoxia-induced vascular leak is, at
least in part, controlled by adenosine. In vitro and in vivo
studies indicated that endogenously generated adenosine,
through activation of PMN adenosine AdoRA2A/2B recep-
tors, functions as an anti-adhesive signal for PMN binding
to microvascular endothelia [47, 64, 110]. Other studies
revealed that adenosine derived via nucleotide phosphohy-
drolysis is critical in eliciting decreases in endothelial
paracellular permeability [7] and that such responses are
dramatically enhanced by hypoxia [14, 15]. In addition,
some studies have suggested that uptake of adenosine by
equilibrative nucleoside transporters (ENTs) in cultured
myocardial cells are decreased during hypoxia. This might
resemble an additional cellular strategy to increase extra-
cellular levels of adenosine during hypoxia [111]. However,
this has not yet been investigated within the endothelium or
the vasculature, and the physiological relevance of this
adaptive pathway currently remains unclear.
Increased adenosine signaling by hypoxia
Several studies had demonstrated a functional role for
hypoxia-regulated CD39 and CD73 in promoting endothe-
lial permeability [14, 15, 47], however, the role of signal
transduction via endothelial adenosine receptors in the
post-hypoxic vasculature remained unclear until recently.
In order to identify changes in endpoint signaling (i.e.,
adenosine receptor activation) in the post-hypoxic endo-
thelium, we profiled the relative expression of adenosine
receptors in normoxic and hypoxic endothelial cells.
Interestingly, these experiments demonstrated that the
Purine signaling during neutrophilYendothelial interactions 235AdoRA2B was selectively induced by hypoxia, and that all
other isoforms were either not changed (AdoRA3)o r
significantly down-regulated (AdoRA1 and AdoRA2A)
[14]. Such microarray results were verified by real-time
PCR and measurement of surface protein levels and
consistently confirmed selective induction of the AdoRA2B
receptor by hypoxia. To determine whether such hypoxia-
induced AdoRA2B expression was functional, endothelial
permeability assays were employed using the selective
AdoRA2B antagonist MRS 1754 [112] and demonstrated a
significantly shift in the adenosine dose-response curve
suggesting that AdoRA2B responses are amplified in post-
hypoxic endothelia. However, further studies in vivo to
verify these in vitro findings in genetically engineered
animals using targeted deletion of individual adenosine
receptors have yet to be performed to follow up on these
observations.
Nucleotide and inosine signaling
Purine signaling is presently a field of intense investigation.
Adenosine as an extracellular nucleoside interacts via P1
receptors. Four P1 receptor subtypes have been identified
until now, namely AdoRA1, AdoRA2A, AdoRA2B and
AdoRA3 and the growth hormone secretagogue receptor
GHSR [60]. Extracellular nucleotides as signaling mole-
cules interact through to different categories of P2-types
of cell surface receptors: P2Y type G protein coupled
receptors, and P2X type ligand gated ion channels. Eight
subtypes of P2Y receptors have been characterized at
present, which are either activated by the adenine nucleo-
tides ATP or ADP or respectively by the uridine nucleo-
tides UTP or UDP. One P2Y subtype is activated by both,
adenine and uridine nucleotides [113Y116]. However, there
can be large differences between different species (e.g., be-
tween human and rat) with regard to P2 receptor se-
lectivity for adenine or uridine nucleotides [117]. Despite
of the fact that the vascular endothelium and multiple cell
types of the immune system (including PMN) express
different P2 receptors [113, 118], only very little is known
about the effect of nucleotide signaling on neutrophilY
endothelial interaction. In fact, the cell physiology of these
receptors and the precise function of the multiple P2
receptor subtypes remains to be understood. As currently
selective blockers of these receptors are being synthesized,
we can soon hope for a more precise understanding of how
nucleotide signaling modulates immune function [119].
There is no unequivocal evidence that AMP can function
as a signaling molecule. Recently, Inbe et al. suggested that
the orphan receptor GPR80/99 may function as an AMP
receptor [120]. In contrast, there is now convincing evi-
dence that GPR80/99 binds a-ketoglutarate, thereby func-
tioning as receptor for citric acid cycle intermediates [121].
In addition, other studies demonstrated that GPR80/99
does not bind adenosine or AMP [122]. Therefore, there
is now consensus that GPR80/99 is not a nucleotide re-
ceptor [123].
In contrast to adenosine, which has for long been
considered an important modulator of immune function
and inflammation, its major degradation product inosine
was originally thought to have no biological effects. How-
ever, some recent studies have suggested that inosine itself
may influence immune function and tissue protection [61].
Similar to adenosine, inosine concentrations are increased
during hypoxia and during ischemia/reperfusion [124]. As
such, inosine was found to bind to the adenosine AdoRA3
receptor subtype and cause mast cell degranulation [125]
or cutaneous vasodilatation [126]. In addition, inosine was
found to be involved in the down-regulation of tissue
damage under different inflammatory conditions in vivo
via activation of AdoRA2A and AdoRA3 adenosine re-
ceptors [127]. However, specific inosine receptors have
not yet been described. In addition, it remains unclear
whether endogenously produced inosine is sufficient to ex-
ert tissue protective influences in vivo, particularly since
the AdoRA3 receptors show only a low affinity for inosine.
However, interstitial concentrations of inosine may be high
enough to activate AdoRA3 receptors during pathophysio-
logical states such as tissue hypoxia [125]. In addition, it is
possible that inosine signaling may contribute to the effects
of adenosine signaling, since exogenous administration of
large doses of inosine were found to decrease ischemia
reperfusion injury in several tissues [61, 125, 128]. Taken
together, the overall contribution of inosine signaling to the
regulation of the vascular function remains to be seen.
Potential therapeutic developments
Several inflammatory diseases (e.g., sepsis, acute respira-
tory failure, colitis) are characterized by vascular barrier
dysfunction, leading to fluid extravasation and edema
formation [129Y131]. As outlined above, endothelial nuc-
leoside signaling creates the potential for therapeutically
modulating the vascular barrier function. For example,
promoting vascular adenosine signaling by increasing ex-
tracellular adenosine generation, activation of specific
vascular adenosine receptors, or impeding with adenosine
breakdown may potentially dampen vascular barrier im-
pairment during hypoxia and inflammation. Several exper-
imental studies have examined this approach. Cohen et al.
investigated the influence of the adenosine deaminase in-
hibitor 20-deoxy-coformycin (pentostatin) in an animal
model of sepsis (cecal ligation and puncture model)
[132]. Using intravital microscopy, the authors demon-
strated that septic mice treated with pentostatin revealed
decreased leukocyte rolling and adhesion. In addition, cir-
culating levels of interleukin-6 and tumor-necrosis-factor-a
were decreased, and survival was increased after 48 h. At
the same time, leakage of fluorescein-isothiocyanate-
labeled albumin was decreased following pentostatin
treatment, suggesting that inhibition of adenosine break-
down during sepsis is associated with improved vascular
barrier function and decreased inflammatory activation. An
alternate strategy to promote vascular adenosine signaling
may include administration of soluble nucleotidase. As
outlined above, nucleotidases convert AMP to adenosine,
thereby increasing adenosine levels. Using this principle, it
was recently shown that administration of 5-nucleotidase to
236 T. Weissmuller et al.mice during hypoxia significantly diminished vascular leak
syndrome [81]. Moreover, we recently demonstrated that
administration of the specific AdoRA2B antagonist MRS
1754 is associated with decreased endothelial adenosine
responses, causing increased leakage of 70 kD dextran
molecules [14]. These studies were confirmed using an in
vivo model of pulmonary barrier function, showing in-
creased albumin leakage after hypoxia exposure in mice
treated with MRS 1754 [81]. These experiments suggest
that therapeutic use of a specific agonist of the AdoRA2B
may dampen edema and fluid extravasation in patients
suffering from inflammatory vascular leak syndrome(s).
Despite of the fact that our understanding of neutrophilY
endothelial interaction during inflammation and hypoxia
has considerably advanced over the last years, and purine
metabolism and signaling clearly offers novel therapeutic
targets in the treatment of inflammation, these experimen-
tally derived ideas have yet to be fully integrated into
clinical practice.
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